Literature DB >> 9413459

Pyoderma gangrenosum and its treatment.

R J Powell1, M R Holbrook, A Stevens.   

Abstract

Entities:  

Mesh：

Year:  1997        PMID： 9413459     DOI： 10.1016/S0140-6736(05)63568-4

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

Review 1.  Extraintestinal manifestations of inflammatory bowel disease.

Authors:  Folashade A Jose; Melvin B Heyman
Journal:  J Pediatr Gastroenterol Nutr       Date:  2008-02       Impact factor: 2.839

2.  Disseminated refractory pyoderma gangraenosum during an ulcerative colitis flare. Treatment with infliximab.

Authors:  Vasiliki A Zampeli; Undine Lippert; Georgios Nikolakis; Evgenia Makrantonaki; Thrasivoulos G Tzellos; Ulf Krause; Christos C Zouboulis
Journal:  J Dermatol Case Rep       Date:  2015-09-30

Review 3.  Skin Manifestations of Inflammatory Bowel Disease.

Authors:  Thomas Greuter; Alexander Navarini; Stephan R Vavricka
Journal:  Clin Rev Allergy Immunol       Date:  2017-12       Impact factor: 8.667

4.  Treatment of pyoderma gangrenosum with infliximab in Crohn's disease.

Authors:  Mark S Sapienza; Sidney Cohen; Anthony J Dimarino
Journal:  Dig Dis Sci       Date:  2004-09       Impact factor: 3.199

Review 5.  Neutrophilic folliculitis and the spectrum of pyoderma gangrenosum in inflammatory bowel disease.

Authors:  A P Ruhl; J E Ganz; S J Bickston
Journal:  Dig Dis Sci       Date:  2006-12-08       Impact factor: 3.487

Review 6.  Extraintestinal Manifestations of Inflammatory Bowel Disease.

Authors:  Stephan R Vavricka; Alain Schoepfer; Michael Scharl; Peter L Lakatos; Alexander Navarini; Gerhard Rogler
Journal:  Inflamm Bowel Dis       Date:  2015-08       Impact factor: 5.325
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.